Potassium canrenoate
From Wikipedia, the free encyclopedia
| Systematic (IUPAC) name | |
|---|---|
|
potassium 3-[(8R,9S,10R,13S,14S,17R)-
17-hydroxy-10,13-dimethyl-3-oxo-2,8,9, 11,12,14,15,16-octahydro-1H-cyclopenta[a] phenanthren-17-yl]propanoate |
|
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration |
Intravenous |
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Excretion | Renal and fecal |
| Identifiers | |
| CAS Registry Number | 2181-04-6 |
| ATC code | C03DA02 |
| PubChem | CID: 656614 |
| DrugBank | DB09015 |
| ChemSpider | 570975 |
| UNII | M671F9NLEA |
| ChEMBL | CHEMBL1371200 |
| Synonyms | SC-14266 |
| Chemical data | |
| Formula | C22H29KO4 |
| Molecular mass | 396.5616 g/mol |
|
|
|
|
| |
Potassium canrenoate (INN, JAN) or canrenoate potassium (USAN) (brand names Venactone, Soldactone), the potassium salt of canrenoic acid, is an aldosterone antagonist.[1] Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body. Potassium canrenoate is not licensed in the UK, but may sometimes be prescribed off-licence to treat oedema. It is given intravenously.
See also[edit]
References[edit]
- ^ R.A. Hill; H.L.J. Makin; D.N. Kirk; G.M. Murphy (23 May 1991). Dictionary of Steroids. CRC Press. pp. 656–. ISBN 978-0-412-27060-4.
|
|
|
|
|
|
| This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |

